Half-antibody functionalized lipid-polymer hybrid nanoparticles for targeted drug delivery to carcinoembryonic antigen presenting pancreatic cancer cells.
Current chemotherapy regimens against pancreatic cancer are met with little success as poor tumor vascularization significantly limits the delivery of oncological drugs. High-dose targeted drug delivery, through which a drug delivery vehicle releases a large payload upon tumor localization, is thus a promising alternative strategy against this lethal disease. Herein, we synthesize anti-carcinoembryonic antigen (CEA) half-antibody conjugated lipid-polymer hybrid nanoparticles and characterize their ligand conjugation yields, physicochemical properties, and targeting ability against pancreatic cancer cells. Under the same drug loading, the half-antibody targeted nanoparticles show enhanced cancer killing effect compared to the corresponding nontargeted nanoparticles.
Hu
Che-Ming Jack
CM
Department of Nanoengineering and Moores Cancer Center, University of California San Diego, La Jolla, California 92093, USA.
Kaushal
Sharmeela
S
Tran Cao
Hop S
HS
Aryal
Santosh
S
Sartor
Marta
M
Esener
Sadik
S
Bouvet
Michael
M
Zhang
Liangfang
L
D002272:Carcinoembryonic Antigen / Q000378:metabolism*; D002460:Cell Line; D002851:Chromatography, High Pressure Liquid; D016503:Drug Delivery Systems / Q000379:methods*; D006801:Humans; D008055:Lipids / Q000737:chemistry*; D053758:Nanoparticles / Q000737:chemistry*; D017239:Paclitaxel / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism*; D011108:Polymers / Q000737:chemistry*
D002272:Carcinoembryonic Antigen; D008055:Lipids; D011108:Polymers; D017239:Paclitaxel
Bioconjug Chem. 1993 Sep-Oct;4(5):347-52
8274518
Small. 2006 Feb;2(2):209-15
17193022
J Immunol Methods. 2001 Jul 1;253(1-2):195-208
11384681
Science. 2009 Jun 12;324(5933):1457-61
19460966
CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
19474385
Nat Nanotechnol. 2008 Mar;3(3):145-50
18654486
Cancer. 1973 Feb;31(2):324-7
4687879
Nature. 1979 Jun 21;279(5715):679-85
221835
Biomaterials. 2009 Mar;30(8):1627-34
19111339
ChemMedChem. 2007 Sep;2(9):1268-71
17600796
Anal Bioanal Chem. 2007 May;388(1):279-86
17393156
J Gastrointest Surg. 2008 Nov;12(11):1938-50
18665430
ACS Nano. 2008 Aug;2(8):1696-702
19206374
Bioconjug Chem. 2001 Mar-Apr;12(2):220-8
11312683
Nat Protoc. 2007;2(5):1152-65
17546006
Br J Cancer. 1998 Jul;78(2):181-8
9683291
FEBS Lett. 1997 Aug 11;413(1):177-80
9287139
Adv Drug Deliv Rev. 1999 Nov 10;40(1-2):103-127
10837783
Cancer. 2007 Aug 1;110(3):525-33
17577216
Cancer Chemother Pharmacol. 2009 Feb;63(3):529-33
18766341